Disease Information
General Information of the Disease (ID: DIS00079)
| Name |
Pleural mesothelioma
|
|---|---|
| ICD |
ICD-11: 2C26
|
| Resistance Map |
Type(s) of Resistant Mechanism of This Disease
Drug Resistance Data Categorized by Drug
Approved Drug(s)
6 drug(s) in total
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: Pvt1 oncogene (PVT1) | [1] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Resistant Drug | Cisplatin | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
| Cell proliferation | Activation | hsa05200 | ||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| NCI-H2052 cells | Lung | Homo sapiens (Human) | CVCL_1518 | |
| NCI-H2452 cells | Lung | Homo sapiens (Human) | CVCL_1553 | |
| NCI-H28 cells | Lung | Homo sapiens (Human) | CVCL_1555 | |
| HCT-4012 cells | Lung | Homo sapiens (Human) | CVCL_IT30 | |
| HP10 cells | Lung | Homo sapiens (Human) | N.A. | |
| HP3 cells | Lung | Homo sapiens (Human) | CVCL_C311 | |
| HP5 cells | Lung | Homo sapiens (Human) | N.A. | |
| HP7 cells | Lung | Homo sapiens (Human) | N.A. | |
| HP9 cells | Lung | Homo sapiens (Human) | N.A. | |
| MET-5A cells | Lung | Homo sapiens (Human) | CVCL_3749 | |
| Meso cells | Lung | Homo sapiens (Human) | CVCL_5759 | |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
MTS assay | |||
| Mechanism Description | c-Myc and PVT1 co-amplification is frequent in MPM. C-MYC and PVT1 cooperation helps to stimulate proliferation, decrease sensitivity to platinum therapy, and reduce apoptosis. Both genes also help to regulate apoptosis-related genes, with C-MYC revealing a tendency to maintain a balance between pro-apoptotic and anti-apoptotic genes, whereas PVT1 revealed a tendency to upregulate pro-apoptotic genes and downregulate anti-apoptotic genes, thereby helping to suppress apoptosis. | |||
| Key Molecule: hsa-mir-15a | [2] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Resistant Drug | Cisplatin | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
SYBR Green-based assay | |||
| Mechanism Description | Expression of miR-15a, miR-16 and miR-34a was downregulated in MPM cells with acquired drug resistance. Transfection with miR-15a or miR-16 mimics reversed the resistance to cisplatin, gemcitabine or vinorelbine, whereas miR-34a reversed cisplatin and vinorelbine resistance only. | |||
| Key Molecule: hsa-mir-15a | [2] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Resistant Drug | Cisplatin | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
SYBR Green-based assay | |||
| Mechanism Description | Expression of miR-15a, miR-16 and miR-34a was downregulated in MPM cells with acquired drug resistance. Transfection with miR-15a or miR-16 mimics reversed the resistance to cisplatin, gemcitabine or vinorelbine, whereas miR-34a reversed cisplatin and vinorelbine resistance only. | |||
| Key Molecule: hsa-mir-16 | [2] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Resistant Drug | Cisplatin | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
SYBR Green-based assay | |||
| Mechanism Description | Expression of miR-15a, miR-16 and miR-34a was downregulated in MPM cells with acquired drug resistance. Transfection with miR-15a or miR-16 mimics reversed the resistance to cisplatin, gemcitabine or vinorelbine, whereas miR-34a reversed cisplatin and vinorelbine resistance only. | |||
| Key Molecule: hsa-mir-16 | [2] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Resistant Drug | Cisplatin | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
SYBR Green-based assay | |||
| Mechanism Description | Expression of miR-15a, miR-16 and miR-34a was downregulated in MPM cells with acquired drug resistance. Transfection with miR-15a or miR-16 mimics reversed the resistance to cisplatin, gemcitabine or vinorelbine, whereas miR-34a reversed cisplatin and vinorelbine resistance only. | |||
| Key Molecule: Forkhead box protein O3 (FOXO3) | [2] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Resistant Drug | Cisplatin | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
SYBR Green-based assay | |||
| Mechanism Description | Expression of miR-15a, miR-16 and miR-34a was downregulated in MPM cells with acquired drug resistance. Transfection with miR-15a or miR-16 mimics reversed the resistance to cisplatin, gemcitabine or vinorelbine, whereas miR-34a reversed cisplatin and vinorelbine resistance only. | |||
| Key Molecule: Forkhead box protein O3 (FOXO3) | [2] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Resistant Drug | Cisplatin | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
SYBR Green-based assay | |||
| Mechanism Description | Expression of miR-15a, miR-16 and miR-34a was downregulated in MPM cells with acquired drug resistance. Transfection with miR-15a or miR-16 mimics reversed the resistance to cisplatin, gemcitabine or vinorelbine, whereas miR-34a reversed cisplatin and vinorelbine resistance only. | |||
|
|
||||
| Key Molecule: Myc proto-oncogene protein (MYC) | [1] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Resistant Drug | Cisplatin | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| Cell Pathway Regulation | Cell proliferation | Activation | hsa05200 | |
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| NCI-H2052 cells | Lung | Homo sapiens (Human) | CVCL_1518 | |
| NCI-H2452 cells | Lung | Homo sapiens (Human) | CVCL_1553 | |
| NCI-H28 cells | Lung | Homo sapiens (Human) | CVCL_1555 | |
| HCT-4012 cells | Lung | Homo sapiens (Human) | CVCL_IT30 | |
| HP10 cells | Lung | Homo sapiens (Human) | N.A. | |
| HP3 cells | Lung | Homo sapiens (Human) | CVCL_C311 | |
| HP5 cells | Lung | Homo sapiens (Human) | N.A. | |
| HP7 cells | Lung | Homo sapiens (Human) | N.A. | |
| HP9 cells | Lung | Homo sapiens (Human) | N.A. | |
| MET-5A cells | Lung | Homo sapiens (Human) | CVCL_3749 | |
| Meso cells | Lung | Homo sapiens (Human) | CVCL_5759 | |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
MTS assay | |||
| Mechanism Description | c-Myc and PVT1 co-amplification is frequent in MPM. C-MYC and PVT1 cooperation helps to stimulate proliferation, decrease sensitivity to platinum therapy, and reduce apoptosis. Both genes also help to regulate apoptosis-related genes, with C-MYC revealing a tendency to maintain a balance between pro-apoptotic and anti-apoptotic genes, whereas PVT1 revealed a tendency to upregulate pro-apoptotic genes and downregulate anti-apoptotic genes, thereby helping to suppress apoptosis. | |||
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: hsa-mir-16 | [3] | |||
| Sensitive Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Sensitive Drug | Gemcitabine | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MET-5A cells | Lung | Homo sapiens (Human) | CVCL_3749 |
| In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
| Experiment for Molecule Alteration |
RT-qPCR | |||
| Experiment for Drug Resistance |
MTT assay; Colony formation assay | |||
| Mechanism Description | Growth inhibition caused by miR-16 correlated with downregulation of target genes including Bcl-2 and CCND1, and miR-16 re-expression sensitised MPM cells to pemetrexed and gemcitabine. | |||
|
|
||||
| Key Molecule: Apoptosis regulator Bcl-2 (BCL2) | [3] | |||
| Sensitive Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Sensitive Drug | Gemcitabine | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MET-5A cells | Lung | Homo sapiens (Human) | CVCL_3749 |
| In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
| Experiment for Molecule Alteration |
Western blotting analysis | |||
| Experiment for Drug Resistance |
MTT assay; Colony formation assay | |||
| Mechanism Description | Growth inhibition caused by miR-16 correlated with downregulation of target genes including Bcl-2 and CCND1, and miR-16 re-expression sensitised MPM cells to pemetrexed and gemcitabine. | |||
| Key Molecule: G1/S-specific cyclin-D1 (CCND1) | [3] | |||
| Sensitive Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Sensitive Drug | Gemcitabine | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MET-5A cells | Lung | Homo sapiens (Human) | CVCL_3749 |
| In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
| Experiment for Molecule Alteration |
Western blotting analysis | |||
| Experiment for Drug Resistance |
MTT assay; Colony formation assay | |||
| Mechanism Description | Growth inhibition caused by miR-16 correlated with downregulation of target genes including Bcl-2 and CCND1, and miR-16 re-expression sensitised MPM cells to pemetrexed and gemcitabine. | |||
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: hsa-mir-149 | [4] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Resistant Drug | Paclitaxel | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| In Vitro Model | A549 cells | Lung | Homo sapiens (Human) | CVCL_0023 |
| H69 cells | Lung | Homo sapiens (Human) | CVCL_8121 | |
| H69AR cells | Lung | Homo sapiens (Human) | CVCL_3513 | |
| MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 | |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
MTT assay | |||
| Mechanism Description | micro-RNA149 confers taxane resistance to malignant mesothelioma cells via upregulation of P-glycoprotein expression. | |||
|
|
||||
| Key Molecule: ATP-binding cassette sub-family B5 (ABCB5) | [4] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Resistant Drug | Paclitaxel | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| In Vitro Model | A549 cells | Lung | Homo sapiens (Human) | CVCL_0023 |
| H69 cells | Lung | Homo sapiens (Human) | CVCL_8121 | |
| H69AR cells | Lung | Homo sapiens (Human) | CVCL_3513 | |
| MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 | |
| Experiment for Molecule Alteration |
Western blot analysis | |||
| Experiment for Drug Resistance |
MTT assay | |||
| Mechanism Description | micro-RNA149 confers taxane resistance to malignant mesothelioma cells via upregulation of P-glycoprotein expression. | |||
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: Thymidylate synthase (TYMS) | [5] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Resistant Drug | Pemetrexed | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| Plat-A cells | Hepato | Homo sapiens (Human) | CVCL_B489 | |
| TCC-MESO-2 cells | Bone and hypodermis | Homo sapiens (Human) | CVCL_E264 | |
| Experiment for Molecule Alteration |
Western blotting assay | |||
| Experiment for Drug Resistance |
CCK8 assay | |||
| Mechanism Description | TYMS overexpression significantly increased drug resistance in the parental cells.The results of chromatin immunoprecipitation-quantitative polymerase chain reaction (ChIP-qPCR) assays suggested that H3K27 acetylation in the 5'-UTR of TYMS may promote its expression in drug-resistant cells. | |||
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: hsa-mir-379 | [6] | |||
| Sensitive Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Sensitive Drug | Pemetrexed | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell invasion | Inhibition | hsa05200 | |
| Cell proliferation | Inhibition | hsa05200 | ||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| ACC-MESO1 cells | Lung | Homo sapiens (Human) | CVCL_5113 | |
| ACC-MESO4 cells | Lung | Homo sapiens (Human) | CVCL_5114 | |
| NCI-H2052 cells | Lung | Homo sapiens (Human) | CVCL_1518 | |
| NCI-H2452 cells | Lung | Homo sapiens (Human) | CVCL_1553 | |
| NCI-H28 cells | Lung | Homo sapiens (Human) | CVCL_1555 | |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
MTS assay | |||
| Mechanism Description | miR-379 and miR-411 play a key role in the carcinogenesis of MPM cells by targeting IL-18 and contributing to the sensitivity of MPM cells to SAHA and PEM. | |||
| Key Molecule: hsa-mir-411 | [6] | |||
| Sensitive Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Sensitive Drug | Pemetrexed | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell invasion | Inhibition | hsa05200 | |
| Cell proliferation | Inhibition | hsa05200 | ||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| ACC-MESO1 cells | Lung | Homo sapiens (Human) | CVCL_5113 | |
| ACC-MESO4 cells | Lung | Homo sapiens (Human) | CVCL_5114 | |
| NCI-H2052 cells | Lung | Homo sapiens (Human) | CVCL_1518 | |
| NCI-H2452 cells | Lung | Homo sapiens (Human) | CVCL_1553 | |
| NCI-H28 cells | Lung | Homo sapiens (Human) | CVCL_1555 | |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
MTS assay | |||
| Mechanism Description | miR-379 and miR-411 play a key role in the carcinogenesis of MPM cells by targeting IL-18 and contributing to the sensitivity of MPM cells to SAHA and PEM. | |||
| Key Molecule: hsa-mir-16 | [3] | |||
| Sensitive Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Sensitive Drug | Pemetrexed | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MET-5A cells | Lung | Homo sapiens (Human) | CVCL_3749 |
| In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
| Experiment for Molecule Alteration |
RT-qPCR | |||
| Experiment for Drug Resistance |
MTT assay; Colony formation assay | |||
| Mechanism Description | Growth inhibition caused by miR-16 correlated with downregulation of target genes including Bcl-2 and CCND1, and miR-16 re-expression sensitised MPM cells to pemetrexed and gemcitabine. | |||
|
|
||||
| Key Molecule: Interleukin-18 (IL18) | [6] | |||
| Sensitive Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Sensitive Drug | Pemetrexed | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell invasion | Inhibition | hsa05200 | |
| Cell proliferation | Inhibition | hsa05200 | ||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| ACC-MESO1 cells | Lung | Homo sapiens (Human) | CVCL_5113 | |
| ACC-MESO4 cells | Lung | Homo sapiens (Human) | CVCL_5114 | |
| NCI-H2052 cells | Lung | Homo sapiens (Human) | CVCL_1518 | |
| NCI-H2452 cells | Lung | Homo sapiens (Human) | CVCL_1553 | |
| NCI-H28 cells | Lung | Homo sapiens (Human) | CVCL_1555 | |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
MTS assay | |||
| Mechanism Description | miR-379 and miR-411 play a key role in the carcinogenesis of MPM cells by targeting IL-18 and contributing to the sensitivity of MPM cells to SAHA and PEM. | |||
| Key Molecule: Apoptosis regulator Bcl-2 (BCL2) | [3] | |||
| Sensitive Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Sensitive Drug | Pemetrexed | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MET-5A cells | Lung | Homo sapiens (Human) | CVCL_3749 |
| In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
| Experiment for Molecule Alteration |
Western blotting analysis | |||
| Experiment for Drug Resistance |
MTT assay; Colony formation assay | |||
| Mechanism Description | Growth inhibition caused by miR-16 correlated with downregulation of target genes including Bcl-2 and CCND1, and miR-16 re-expression sensitised MPM cells to pemetrexed and gemcitabine. | |||
| Key Molecule: G1/S-specific cyclin-D1 (CCND1) | [3] | |||
| Sensitive Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Sensitive Drug | Pemetrexed | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MET-5A cells | Lung | Homo sapiens (Human) | CVCL_3749 |
| In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
| Experiment for Molecule Alteration |
Western blotting analysis | |||
| Experiment for Drug Resistance |
MTT assay; Colony formation assay | |||
| Mechanism Description | Growth inhibition caused by miR-16 correlated with downregulation of target genes including Bcl-2 and CCND1, and miR-16 re-expression sensitised MPM cells to pemetrexed and gemcitabine. | |||
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: hsa-mir-15a | [2] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Resistant Drug | Vinorelbine | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
SYBR Green-based assay | |||
| Mechanism Description | Expression of miR-15a, miR-16 and miR-34a was downregulated in MPM cells with acquired drug resistance. Transfection with miR-15a or miR-16 mimics reversed the resistance to cisplatin, gemcitabine or vinorelbine, whereas miR-34a reversed cisplatin and vinorelbine resistance only. | |||
| Key Molecule: hsa-mir-15a | [2] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Resistant Drug | Vinorelbine | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
SYBR Green-based assay | |||
| Mechanism Description | Expression of miR-15a, miR-16 and miR-34a was downregulated in MPM cells with acquired drug resistance. Transfection with miR-15a or miR-16 mimics reversed the resistance to cisplatin, gemcitabine or vinorelbine, whereas miR-34a reversed cisplatin and vinorelbine resistance only. | |||
| Key Molecule: hsa-mir-16 | [2] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Resistant Drug | Vinorelbine | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
SYBR Green-based assay | |||
| Mechanism Description | Expression of miR-15a, miR-16 and miR-34a was downregulated in MPM cells with acquired drug resistance. Transfection with miR-15a or miR-16 mimics reversed the resistance to cisplatin, gemcitabine or vinorelbine, whereas miR-34a reversed cisplatin and vinorelbine resistance only. | |||
| Key Molecule: hsa-mir-16 | [2] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Resistant Drug | Vinorelbine | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
SYBR Green-based assay | |||
| Mechanism Description | Expression of miR-15a, miR-16 and miR-34a was downregulated in MPM cells with acquired drug resistance. Transfection with miR-15a or miR-16 mimics reversed the resistance to cisplatin, gemcitabine or vinorelbine, whereas miR-34a reversed cisplatin and vinorelbine resistance only. | |||
| Key Molecule: Forkhead box protein O3 (FOXO3) | [2] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Resistant Drug | Vinorelbine | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
SYBR Green-based assay | |||
| Mechanism Description | Expression of miR-15a, miR-16 and miR-34a was downregulated in MPM cells with acquired drug resistance. Transfection with miR-15a or miR-16 mimics reversed the resistance to cisplatin, gemcitabine or vinorelbine, whereas miR-34a reversed cisplatin and vinorelbine resistance only. | |||
| Key Molecule: Forkhead box protein O3 (FOXO3) | [2] | |||
| Resistant Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Resistant Drug | Vinorelbine | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
SYBR Green-based assay | |||
| Mechanism Description | Expression of miR-15a, miR-16 and miR-34a was downregulated in MPM cells with acquired drug resistance. Transfection with miR-15a or miR-16 mimics reversed the resistance to cisplatin, gemcitabine or vinorelbine, whereas miR-34a reversed cisplatin and vinorelbine resistance only. | |||
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: hsa-mir-379 | [6] | |||
| Sensitive Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Sensitive Drug | Vorinostat | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell invasion | Inhibition | hsa05200 | |
| Cell proliferation | Inhibition | hsa05200 | ||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| ACC-MESO1 cells | Lung | Homo sapiens (Human) | CVCL_5113 | |
| ACC-MESO4 cells | Lung | Homo sapiens (Human) | CVCL_5114 | |
| NCI-H2052 cells | Lung | Homo sapiens (Human) | CVCL_1518 | |
| NCI-H2452 cells | Lung | Homo sapiens (Human) | CVCL_1553 | |
| NCI-H28 cells | Lung | Homo sapiens (Human) | CVCL_1555 | |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
MTS assay | |||
| Mechanism Description | miR-379 and miR-411 play a key role in the carcinogenesis of MPM cells by targeting IL-18 and contributing to the sensitivity of MPM cells to SAHA and PEM. | |||
| Key Molecule: hsa-mir-411 | [6] | |||
| Sensitive Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Sensitive Drug | Vorinostat | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell invasion | Inhibition | hsa05200 | |
| Cell proliferation | Inhibition | hsa05200 | ||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| ACC-MESO1 cells | Lung | Homo sapiens (Human) | CVCL_5113 | |
| ACC-MESO4 cells | Lung | Homo sapiens (Human) | CVCL_5114 | |
| NCI-H2052 cells | Lung | Homo sapiens (Human) | CVCL_1518 | |
| NCI-H2452 cells | Lung | Homo sapiens (Human) | CVCL_1553 | |
| NCI-H28 cells | Lung | Homo sapiens (Human) | CVCL_1555 | |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
MTS assay | |||
| Mechanism Description | miR-379 and miR-411 play a key role in the carcinogenesis of MPM cells by targeting IL-18 and contributing to the sensitivity of MPM cells to SAHA and PEM. | |||
|
|
||||
| Key Molecule: Interleukin-18 (IL18) | [6] | |||
| Sensitive Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Sensitive Drug | Vorinostat | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell invasion | Inhibition | hsa05200 | |
| Cell proliferation | Inhibition | hsa05200 | ||
| In Vitro Model | MSTO-211H cells | Lung | Homo sapiens (Human) | CVCL_1430 |
| ACC-MESO1 cells | Lung | Homo sapiens (Human) | CVCL_5113 | |
| ACC-MESO4 cells | Lung | Homo sapiens (Human) | CVCL_5114 | |
| NCI-H2052 cells | Lung | Homo sapiens (Human) | CVCL_1518 | |
| NCI-H2452 cells | Lung | Homo sapiens (Human) | CVCL_1553 | |
| NCI-H28 cells | Lung | Homo sapiens (Human) | CVCL_1555 | |
| Experiment for Molecule Alteration |
qRT-PCR | |||
| Experiment for Drug Resistance |
MTS assay | |||
| Mechanism Description | miR-379 and miR-411 play a key role in the carcinogenesis of MPM cells by targeting IL-18 and contributing to the sensitivity of MPM cells to SAHA and PEM. | |||
Clinical Trial Drug(s)
1 drug(s) in total
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: PI3-kinase alpha (PIK3CA) | [7] | |||
| Sensitive Disease | Malignant pleural mesothelioma [ICD-11: 2C26.0] | |||
| Molecule Alteration | Missense mutation | p.R88Q (c.263G>A) |
||
| Sensitive Drug | Apitolisib | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | . | . | ||
| Experiment for Molecule Alteration |
DxS allele-specific PCR; qRT-PCR assays; Sanger sequencing assay | |||
| Experiment for Drug Resistance |
CTCAE assay | |||
References
visits since 2022
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.
